Scripps VIVO scripps research logo

  • Index
  • Log in
  • Home
  • People
  • Organizations
  • Research
  • Events
Search form

Triple antiplatelet therapy during percutaneous coronary intervention is associated with improved outcomes including one-year survival - results from the do tirofiban and reopro give similar efficacy outcome trial (target)

Academic Article
uri icon
  • Overview
  • Identity
  • Additional Document Info
  • View All
scroll to property group menus

Overview

authors

  • Chan, A. W.
  • Moliterno, D. J.
  • Berger, P. B.
  • Stone, G. W.
  • DiBattiste, P. M.
  • Yakubov, S. L.
  • Sapp, S. K.
  • Wolski, K.
  • Bhatt, D. L.
  • Topol, Eric

publication date

  • 2003

journal

  • Journal of the American College of Cardiology  Journal

subject areas

  • Angioplasty, Balloon, Coronary
  • Antibodies, Monoclonal
  • Aspirin
  • Combined Modality Therapy
  • Drug Administration Schedule
  • Drug Therapy, Combination
  • Female
  • Humans
  • Immunoglobulin Fab Fragments
  • Louisiana
  • Male
  • Middle Aged
  • Minnesota
  • Myocardial Infarction
  • New York City
  • Ohio
  • Pennsylvania
  • Platelet Aggregation Inhibitors
  • Platelet Glycoprotein GPIIb-IIIa Complex
  • Postoperative Care
  • Premedication
  • Severity of Illness Index
  • Stents
  • Survival Analysis
  • Ticlopidine
  • Treatment Outcome
  • Tyrosine
scroll to property group menus

Identity

International Standard Serial Number (ISSN)

  • 0735-1097

Digital Object Identifier (DOI)

  • 10.1016/s0735-1097(03)00944-6

PubMed ID

  • 14522478
scroll to property group menus

Additional Document Info

start page

  • 1188

end page

  • 1195

volume

  • 42

issue

  • 7

©2019 The Scripps Research Institute | Terms of Use | Powered by VIVO

  • About
  • Contact Us
  • Support